Dr. Christiana (Chris) Bardon

Dr. Christiana (Chris) Bardon is a physician and investor who serves as co-managing partner of MPM BioImpact, a dedicated biotechnology investment firm active across private and public markets. She is the portfolio manager for the firm’s public-market strategies, BioImpact Equities and the Oncology Impact Funds.

Trained as a physician at Harvard Medical School and the Brigham and Women’s Hospital, Bardon also holds bachelor’s and master’s degrees from MIT and an MBA from Harvard Business School. She began her career as an analyst at MPM, spent years as a healthcare analyst at Fidelity Investments covering biotechnology, life-science tools, and diagnostics, and later founded her own fund before merging it onto the MPM platform roughly a decade ago. She is a trustee of the American Association for Cancer Research Foundation, an executive fellow at Harvard Business School, and a member of the Harvard Medical School Board of Fellows.

Bardon appeared on Open Door Salon alongside Elaine Hamm, president and chief executive of Ascend BioVentures, for a conversation recorded after the J.P. Morgan Healthcare Conference on the state of biotech investing. Speaking from the investor’s seat, Bardon argued that the 2020 financing bubble has largely reset, that capital discipline now separates the companies that survive from those that do not, and that artificial intelligence, while transformative on the services and regulatory side, has not yet meaningfully changed the economics of the clinical-trial process that gates drug approval.

Her advice to founders raising capital was to fix on the single value-creating milestone, proof of concept for a drug, and reach it as efficiently as possible. Above all, she prized intellectual honesty: the managers she backs repeatedly, she said, are the ones who can name their own mistakes without defensiveness and improve their process because of them.